PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 31, 2012

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Breast Cancer
Interventions
DRUG

Anthracycline based chemotherapy

standard of care neoadjuvant treatment with anthracycline based chemotherapy

DRUG

taxane-based chemotherapy

neoadjuvant taxane based chemotherapy given as standard of care

Trial Locations (1)

77030

Houston Methodist Hospital, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GE Healthcare

INDUSTRY

collaborator

The Methodist Hospital Research Institute

OTHER

lead

Jenny C. Chang, MD

OTHER

NCT02067416 - PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer | Biotech Hunter | Biotech Hunter